BioLife Solutions BLFS

Beleggen in aandelen beurs New York, Dow Jones index, Nasdaq-100 en S&P500
Plaats reactie
Maarten1977
Forum actieveling
Forum actieveling
Berichten: 804
Lid geworden op: 01 Jul 2012 17:11
waarderingen: 58
Contact:

BioLife Solutions BLFS

Berichtdoor Maarten1977 » 07 Jan 2013 16:00

BioLife Solutions, Inc., a life sciences tools provider, develops, manufactures, and markets patented hypothermic storage and cryopreservation solutions for cells, tissues, and organs. The company’s products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, delayed-onset cell damage, and death. Its HypoThermosol series of products include HypoThermosol FRS, a solution formulated to decrease the free radical accumulation in cells undergoing prolonged hypothermic preservation; and HypoThermosol Purge, a flush solution designed for use during the transitions from normothermic to mild hypothermic to rinse culture media and native fluids from tissue and whole organ systems prior to suspension in a preservation solution. The company’s CryoStor series of products consist of CryoStor CS2, CryoStor CS5, and CryoStor CS10, which are cryopreservation freeze media products designed to mitigate temperature-induced molecular cell stress responses during freezing and thawing. Its BloodStor products comprise BloodStor 55-5 that is pre-formulated with DMSO USP, Dextran-40 USP, and water for injection quality water; and BloodStor 100, which contains DMSO USP. The company also provides custom product formulation and custom packaging; and contract aseptic manufacturing fill and finish services. It markets its proprietary HypoThermosol, CryoStor, and generic BloodStor biopreservation media products to cell therapy companies, pharmaceutical companies, cord blood banks, hair transplant surgeons, and suppliers of cells to the toxicology testing and diagnostic markets. BioLife Solutions, Inc. was founded in 1987 and is based in Bothell, Washington.

http://finance.yahoo.com/q/pr?s=BLFS+Profile" onclick="window.open(this.href);return false;

Onze Tigenix is er klant van.
Minder dan 70,000,000 uitstaande aandelen

"At first glance, the company's balance sheet appears to be weak. BioLife ended the quarter with $155,364 in cash, and $12,991,408 in total debt and accrued interest. When looking at just the headline numbers, such debt levels are indeed concerning. But, as with most things investing, the truth lies below the surface. Most healthcare start-ups choose to fund themselves with equity until they become profitable. That is why most development-stage biotechnology companies have relatively clean balance sheets. But, constant equity offerings lead to dilution, as the number of outstanding shares keeps rising. BioLife, however, has chosen a different funding strategy. The company has chosen to concentrate on debt financing instead. BioLife ended Q2 2012 with 69,679,854 outstanding shares. BioLife ended Q2 2008 with 69,639,854 outstanding shares. But, BioLife's total debt and accrued interest that quarter was $4,081,526. BioLife has been judicious when it comes to issuing new stock, and has chosen to finance itself with debt until it reaches sustainable profitability. While BioLife's debt burden is quite large relative to its existing cash position, it is important to note that this debt is not due in 2012. Or 2013. Rather, the debt and interest are due on January 11, 2016 (per the company's latest 10-Q). Furthermore, BioLife's debt is owed to an investor group that sits on the company's board of directors. One of the concerns that has been holding back BioLife's stock in 2012 is the company's debt burden, originally scheduled to mature in 2013. When the deal was announced, CEO Mike Rice stated that,
"more than ever, our largest investors are pleased with the direction and growth trajectory of the Company and understand that the near-term maturity of debt was seen as an overhang for potential new investors in BioLife stock. The extension of the maturity date until 2016, gives us time and financial flexibility to execute on our current growth ramp and continue to make prudent investments necessary to capture additional market share."

BioLife now has 3 years to reach a stronger financial state, even though it does not need that much time. As part of the debt restructuring, BioLife has issued 2 million warrants to its debtholders, bringing its total amount of outstanding warrants to 7,718,750. The warrants have expiration dates between November 2013 and November 2017. No warrants have been exercised so far this year, and we think that it is unlikely that the warrants will be fully exercised for at least several years, when BioLife's stock price is higher than it is today (assuming that everything goes according to plan). BioLife has reaffirmed its expectation that it will reach sustainable operating cash flow by the end of 2012 when Q2 earnings were released. BioLife did post positive operating cash flow during the first 6 months of 2012, but there were several items that distorted the company's cash flow of $686,007. The primary item was the contribution of $785,112 from deferred rent. Offsetting that was a $410,854 increase in the company's inventory.

BioLife's inventories rose significantly in its latest quarter, rising from $505,956 to $916,810 (an increase of 81.2%). A steep rise in inventories is often a red flag for investors, because it implies that a company is unable to sell its products to customers, or that it has stuffed the channel in prior quarters, and is paying for it now. However, the composition of that inventory matters much more than the headline number. BioLife's inventory increase was driven by a 104.5% increase in raw materials, and a 2,617.14% in work in progress. The company's stock of finished goods, however, fell by 24.48% from $320,688 to $242,238. BioLife's inventory has risen not because it is unable to sell its products, but because it is readying itself for continued growth in demand for its products."

http://seekingalpha.com/article/919961- ... urce=yahoo" onclick="window.open(this.href);return false;


BioLife Solutions Reports Preliminary 2012 Revenue at $5.7 Million; Doubled from 2011
Sales to All Strategic Market Segments up over 2011; Company Generated Positive Cash Flow From Operations in 2012

http://finance.yahoo.com/news/biolife-s ... 00567.html" onclick="window.open(this.href);return false;

Ik volg het aandeel geruime tijd (sinds ik wist dat Tigenix er zaken mee deed) en ben vandaag met 50.000 aandelen ingestapt aan .34
All in op EDAP


Maarten1977
Forum actieveling
Forum actieveling
Berichten: 804
Lid geworden op: 01 Jul 2012 17:11
waarderingen: 58
Contact:

Re: BioLife Solutions BLFS

Berichtdoor Maarten1977 » 08 Jan 2013 06:59

BLFS: Revenue Upside Surprise, Again...
ZacksBy Zacks Equity Research | Zacks – 8 hours ago

Revenue Pre-Announcement Beats Our Estimate. Increasing Price Target to $0.70/share

By Brian Marckx, CFA

This morning (1/7/13) BioLife (OTC Markets:BLFS) pre-announced that Q4 and full-year 2012 revenue are expected to be approximately $2.0 million (~ +158%) and $5.7 million (~ +107%), respectively, which are well ahead or our $1.4 million and $5.0 million estimates. Q4 and 2012 revenue will be a quarterly and annual record for BLFS. This will mark the 10th consecutive quarter that BioLife turned in record revenue and equates to 34% CAGR of revenue since 2007. This morning's press release also notes that Q4 is expected to show positive cash flow from operations.

Management continues to expect strong growth in 2013 from their regenerative medicine business and notes that they are pursuing additional contract manufacturing opportunities. We have updated our model for today's revenue pre-announcement and will do so again when BLFS files their 10-K which is expected by April 1.

We are maintaining our Outperform rating. The update to our model along with an increase in comp multiples since our last update has moved our price target up from $0.50/share to $0.70/share. See our valuation methodology and comp cohort as well as our financial model in our full report on BLFS available here.


For additional research on small-cap stocks, please visit scr.zacks.com.

http://finance.yahoo.com/news/blfs-reve ... 55634.html" onclick="window.open(this.href);return false;
All in op EDAP

Stefan
Forum actieveling
Forum actieveling
Berichten: 479
Lid geworden op: 18 Dec 2012 18:52
waarderingen: 58
Contact:

Re: BioLife Solutions BLFS

Berichtdoor Stefan » 08 Jan 2013 10:55

Ik vind ze niet terug in de databank van Binckbank.
Is wel een interessant aandeel.
Biolase ($1.91)
Senomyx ($1.21)
Thrombogenics (€3,32)

Maarten1977
Forum actieveling
Forum actieveling
Berichten: 804
Lid geworden op: 01 Jul 2012 17:11
waarderingen: 58
Contact:

Re: BioLife Solutions BLFS

Berichtdoor Maarten1977 » 08 Jan 2013 12:55

DHI Global Medical Group Adopts BioLife Solutions' HypoThermosol® as Improved Hair Graft Storage Medium

BOTHELL, Wash., Jan. 8, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract media manufacturer, today announced that DHI Global Medical Group has adopted BioLife's proprietary HypoThermosol cell/tissue storage and shipping medium to improve ex-vivo survival of hair grafts during transplantation procedures.

(Logo: http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO" onclick="window.open(this.href);return false;)

Mike Rice, BioLife Solutions Chief Executive Officer, said, "We have spent the past few years building the value of HypoThermosol as an important biopreservation medium in hair restoration and we believe 2013 will be the year that this market becomes a significant revenue stream for BioLife Solutions. We are very pleased to support DHI Global in its continuous quality improvement initiative. DHI Global joins a growing number of hair restoration clinicians and professionals who understand the value and benefits of transitioning from non-optimized graft storage solutions to using HypoThermosol, which is engineered to better protect cells and tissues exposed to hypothermic biopreservation conditions. Leading hair restoration surgeons around the world have adopted HypoThermosol after seeing improved graft survival and increased patient satisfaction."

DHI Global used volumes of HypoThermosol in its offices in Paris, London, and Athens, with a goal of establishing use of HypoThermosol as a standard of care through its network of more than 30 global locations.

The International Society of Hair Restoration Surgery (ISHRS) estimates that nearly 300,000 surgical hair restoration procedures were performed worldwide in 2010.

About DHI Global Medical Group

Founded in 1970 with now over 30 worldwide affiliated locations, DHI Global Medical Group hair restoration professionals have performed over 150,000 procedures. The company was founded by Mr. K.P. Giotis in Palo Alto, California and has been dedicated solely to the research, diagnosis and treatment of hair and scalp disorders. 42 years later, the DHI technique offers hair loss sufferers across the globe a painless procedure with natural results. For more information please visit http://www.dhiglobal.com" onclick="window.open(this.href);return false;.

http://finance.yahoo.com/news/dhi-globa ... 00335.html" onclick="window.open(this.href);return false;
All in op EDAP

Maarten1977
Forum actieveling
Forum actieveling
Berichten: 804
Lid geworden op: 01 Jul 2012 17:11
waarderingen: 58
Contact:

Re: BioLife Solutions BLFS

Berichtdoor Maarten1977 » 08 Jan 2013 20:40

Nog even waarschuwen: als je BLFS koopt, weet dan dat er momenteel weinig handelsvolume is. Snel kopen en verkopen, leidt meestal tot verlies bij zulke aandelen.
All in op EDAP

Maarten1977
Forum actieveling
Forum actieveling
Berichten: 804
Lid geworden op: 01 Jul 2012 17:11
waarderingen: 58
Contact:

Re: BioLife Solutions BLFS

Berichtdoor Maarten1977 » 09 Jan 2013 21:43

Hun presentatie op het OneMedForum van 8 januari:
http://biolifesolutions.com/biopreserva ... 8-2012.pdf" onclick="window.open(this.href);return false;
All in op EDAP

Maarten1977
Forum actieveling
Forum actieveling
Berichten: 804
Lid geworden op: 01 Jul 2012 17:11
waarderingen: 58
Contact:

Re: BioLife Solutions BLFS

Berichtdoor Maarten1977 » 17 Jan 2013 19:42

"BioLife Solutions plans a global trade show presence in 2013 beginning with Phacilitate’s Cell & Gene Forum in Washington DC, January 28-30. A new exhibit was recently created to illustrate how BioLif e’s clinical grade, serum-free, protein- free, cGMP biopreservation media is used in more than 50 customer clinical trials “head-to-toe”. The booth exhibit was unveiled at ISCT’s 2012 Annual Meeting in Seattle (pictured) and will travel to ISCT’s 2013 meeting in Auckland, New Zealand, April 22-25. For more information regarding BioLife’s upcoming conference schedule, please continue to check our events page."

http://biolifesolutions.com/blog/" onclick="window.open(this.href);return false;
All in op EDAP

Maarten1977
Forum actieveling
Forum actieveling
Berichten: 804
Lid geworden op: 01 Jul 2012 17:11
waarderingen: 58
Contact:

Re: BioLife Solutions BLFS

Berichtdoor Maarten1977 » 27 Jan 2013 20:56

Staat ook in de database van FlandersBio
"FlandersBio offers an up-to-date life sciences database containing all the life sciences companies with biotech activity in Flanders, and all FlandersBio members. The guide provides easy and fast access to the local life sciences community."

http://flandersbio.be/life-sciences-dat ... tions-inc/" onclick="window.open(this.href);return false;
All in op EDAP

Maarten1977
Forum actieveling
Forum actieveling
Berichten: 804
Lid geworden op: 01 Jul 2012 17:11
waarderingen: 58
Contact:

Re: BioLife Solutions BLFS

Berichtdoor Maarten1977 » 01 Feb 2013 16:20

Kom achteraf niet klagen van: "Was ik toen ook maar ingestapt." Enfin: nieuwe posts indien nieuws of koers boven $1.00
All in op EDAP

demon100
Forum actieveling
Forum actieveling
Berichten: 731
Lid geworden op: 13 Dec 2012 10:24
waarderingen: 51
Contact:

Re: BioLife Solutions BLFS

Berichtdoor demon100 » 03 Feb 2013 17:50

Kan ze ook niet vinden , hoe kan je eraan komen bij binckbank ?
Ablynx - euronav - facebook